<?xml version="1.0" encoding="UTF-8"?>
<p id="p0010">COVID-19 soon became an unstoppable disease since an outbreak occurred in December in Wuhan, China.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> The number of cases has increased dramatically, and no approved medications or vaccines are currently available to treat human coronavirus infection. Wang et al.
 <xref rid="bib2" ref-type="bibr">
  <sup>2</sup>
 </xref> reported 124 patients (89.9%) in China who received antiviral therapy with oseltamivir, and 36 of these patients (26.1%) were transferred to the intensive care unit (ICU) and 6 died (4.3%). Holshue et al.
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref> presented the first case to receive intravenous remdesivir in the United States, and the outcome was satisfactory. Lopinavir and ritonavir were associated with improved clinical outcomes in patients with SARS in a non-randomized open-label trial.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> Here, we report five confirmed cases of COVID-19 infection in Taiwan; two were prescribed LPV/r as two tablets twice daily for empirical therapy, and three were not prescribed LPV/r. We describe their diagnosis, clinical course, and novel coronavirus (SARS CoV-2) viral loads during the treatment course.
</p>
